Discussion
BACKGROUND
Langerhans cell histiocytosis (LCH) is a rare multi-system disease with a wide clinical spectrum, but the most frequently affected organs are skeleton (80% of cases), skin (33%), and pituitary (25%). Extraosseus disease includes pulmonary, thymic, hepatobiliary, splenic, gastrointestinal, neurologic, mucocutaneous, head and neck soft-tissue masses and salivary involvement. The disease is more common in the paediatric population. [1]
CLINICAL PERSPECTIVE
LCH is divided into 3 groups (based on the number of lesions, systems involved)
1- Unifocal (localized) form: (70% of cases) Limited to a single or a few bones and may involve the lung.
2- Multifocal unisystem (20% of cases) Multiple bones, reticuloendothelial system, pituitary/hypothalamus.
3- Multifocal, multisystem: (10% of cases) The worst prognosis. Multisystem LCH occurs in two or more organs or body systems or may be spread throughout the body.
LCH may affect low-risk or high-risk organs: Low-risk organs include the skin, bone, lungs, lymph nodes, gastrointestinal tract, pituitary gland. High-risk organs include the liver, spleen, and bone marrow. CNS lesions have their own classification in low and high-risk lesions. [1]
IMAGING PERSPECTIVE
Head and neck involvement in Langerhans cell histiocytosis is common and may include bone and soft-tissue lesions, cervical lymphadenopathy and skin rash.
Craniofacial osseous destruction has been described in association with adjacent soft-tissue infiltration.
The ear is a common site of involvement and its involvement most often manifests as chronic otorrhoea, mastoiditis or otitis (as our patient). Most patients who present ear involvement have multisystem disease. [2]
CT is performed to evaluate the extent of osseous erosion or destruction. Temporal bone destruction (mastoid, external auditory meatus, middle or internal ear) is often associated with an adjacent soft-tissue mass. [2, 3, 4]
MRI shows soft-tissue masses with hyperintense signal on T2-weighted sequences and isointense to hypointense signal on T1-weighted sequences with marked enhancement.
Involvement of the skull base may infiltrate the petrous portion of the temporal bone. [5]
OUTCOME
Biopsy was performed to confirm the diagnosis. Prognosis can be variable (unifocal disease: >95% survival; two organ involvement: 75%; Langerhans cell sarcoma: 50% survival). In head and neck involvement, outcome after chemotherapy is good although recurrences are common, especially in patients with multisystem disease. Treatment is based on vinblastine, prednisolone and metrotexate. [1, 2]
TAKE HOME MESSAGE
- LCH is a rare multi-system disease
- LCH is divided into 3 groups: Unifocal/multifocal, unisystem/multifocal, multisystem form.
- Head and neck involvement in LCH is common (bone and soft-tissue lesions, cervical lymphadenopathies and skin rash)
- Ear involvement is a common and manifests as chronic otorrhoea, mastoiditis or otitis.